Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Can-Fite BioPharma Ltd. CANF
$2.12
+$0.02 (0.95%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
8696343.00000000
-
week52high
11.20
-
week52low
1.52
-
Revenue
810000
-
P/E TTM
-2
-
Beta
0.79114900
-
EPS
-3.45000000
-
Last Dividend
0.00000000
-
Next Earnings Date
25 мая 2023 г. в 04:00
Описание компании
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| H.C. Wainwright | Buy | Buy | 24 сент 2019 г. |
| Maxim Group | Hold | Buy | 09 мар 2018 г. |
| Maxim Group | Buy | Buy | 11 авг 2017 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
All You Need to Know About Can-Fite Biopharma Ltd (CANF) Rating Upgrade to Buy
Zacks Investment Research
10 мая 2023 г. в 13:41
Can-Fite Biopharma Ltd (CANF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding
MarketBeat
02 мая 2023 г. в 13:12
Can-Fite BioPharma Ltd. NYSEAMERICAN: CANF is an Israel-based biotechnology firm that develops small-molecule therapeutic treatments for cancers, inflammatory diseases and sexual dysfunction.
All You Need to Know About CanFite Biopharma Ltd (CANF) Rating Upgrade to Buy
Zacks Investment Research
26 июл 2022 г. в 14:00
CanFite Biopharma Ltd (CANF) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Can-Fite BioPharma Shares Jump After Piclidenoson Data In Psoriasis Trial
Benzinga
29 июн 2022 г. в 07:57
Can-Fite BioPharma Ltd (NYSE: CANF) announced topline results from the COMFORT Phase 3 trial of Piclidenoson in more than 400 adults with moderate to severe plaque psoriasis. The study data show that patients treated with oral Piclidenoson 2 mg or 3 mg twice daily had clinically.